A Look at Five Stocks on Investors’ Radars on Tuesday

The US stock market is trading lower amid a decline in global markets and after consumer price data released by the Labor Department showed that inflation remained flat in July.

Among the stocks that are trending on Tuesday are The Hain Celestial Group, Inc. (NASDAQ:HAIN), StemCells Inc (NASDAQ:STEM), Gogo Inc (NASDAQ:GOGO), Evoke Pharma Inc (NASDAQ:EVOK), and Vipshop Holdings Ltd – ADR (NYSE:VIPS). In this article, we are going to analyze the latest developments surrounding these companies and take a look at some of the investors that reported stakes in them in the latest round of 13F filings.

While there are many metrics that investors can assess in the investment process, hedge fund sentiment is something that is often overlooked. However, hedge funds and other institutional investors allocate significant resources while making their bets and their long-term focus makes them the perfect investors to emulate. This is supported by our research, which determined that following the small-cap stocks that hedge funds are collectively bullish on can help a smaller investor beat the S&P 500 by around 95 basis points per month (see more details here).

violetkaipa/Shutterstock.com

The Hain Celestial Group, Inc. (NASDAQ:HAIN) shares are trading down by more than 27% after the company announced that it will delay the release of its fiscal fourth-quarter results and filing of its annual report due to accounting issues. The company is conducting an independent review after doubts emerged over the accounting of revenue for concessions granted to U.S. distributors. The Hain Celestial Group, Inc. (NASDAQ:HAIN) also expects to miss sales and profit guidance provided earlier. A slew of brokerage houses downgraded the stock, including Barclays, which reduced the rating to ‘Equal-Weight’ and slashed the price target to $43 from $51 earlier. David Tepper’s Appaloosa Management reported a stake containing almost 1.29 million shares of The Hain Celestial Group in its 13F filing for the end of June.

Nano-cap StemCells Inc (NASDAQ:STEM)’s stock has surged by over 87% after the company  entered into a merger agreement with Israeli company Microbot Medical, following which the company will be taken private. As part of the deal, StemCells’ shareholders will own 5% of the new entity while shareholders of Microbot Medical will own the rest of the entity. Jim Simons’ Renaissance Technologies owned 72,932 shares of StemCells at the end of the second quarter.

On the next page, we are going to discuss Gogo Inc (NASDAQ:GOGO), Evoke Pharma Inc (NASDAQ:EVOK) and Vipshop Holdings Ltd – ADR (NYSE:VIPS).

Gogo Inc (NASDAQ:GOGO)’s stock is trading higher on the back of the company winning approval from Chinese regulators to provide in-flight connectivity service on international flights operating in and out of China. The company will start offering services through its partner China Telecom Satellite from October. Gogo Inc (NASDAQ:GOGO)’s President and CEO, Michael Small stated that “We believe China Telecom Satellite will be a very strong and effective partner for China’s in-flight communication market and both parties will extend the cooperation to Chinese airlines in the future.”

Evoke Pharma Inc (NASDAQ:EVOK)’s stock has plunged by over 11% on the back of its results for the second quarter. The company reported a net loss of $0.41 per share, which topped the estimates by $0.02 and was significantly narrower than the net loss of $0.52 per share posted a year earlier. The company did not have any revenue and said it had $4.1 million in cash and cash equivalents at the end of June. “Importantly, we recently completed financings for $14.5 million in gross proceeds to support the continued review and development of potential clinical and regulatory strategies for Gimoti. This represents a significant investment in Evoke, which we believe demonstrates investor confidence in Gimoti’s potential to benefit patients suffering from gastroparesis and helps position us to explore potential options as we work to get Gimoti to market,” Dave Gonyer, R.Ph., President and CEO of Evoke Pharma said in a statement. James A. Silverman’s Opaleye Management owned 130,000 shares of Evoke Pharma heading into the second quarter.

Finally, Vipshop Holdings Ltd – ADR (NYSE:VIPS)’s stock opened higher following the release of its financial results, but is currently trading slightly in the red. The company reported second-quarter revenue of $2.02 billion, which beat analysts’ estimates by $120 million, while EPS of $0.17 surpassed the expectations by $0.02. In addition, Vipshop provided revenue guidance in the range of RMB11.9 billion ($1.79 billion) to RMB12.4 billion ($1.86 billion) for the third quarter. During the second quarter, Ted Kang’s Kylin Management raised its stake in Vipshop Holdings by 15% to 21.79 million shares.

Disclosure: None